RIG Blocking Peptide (C-Term)
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q13278 |
---|
Other Names | Putative protein RIG, Protein regulated in glioma, RIG |
---|---|
Target/Specificity | The synthetic peptide sequence is selected from aa 78-87 of HUMAN RIG |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | RIG |
---|---|
Function | May serve as a molecular marker for or play a role in the malignant progression of glioblastomas. |
Tissue Location | Expressed predominantly in brain and weakly in heart and lung. Expression is reduced or undetectable in cultured glioma cells, primary glioblastoma cells and malignant glioblastoma tumors. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
May serve as a molecular marker for or play a role in the malignant progression of glioblastomas.
References
Ligon A.H.,et al.Oncogene 14:1075-1081(1997).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.